1. Immunology and Inflammation

Systemic hypoxia inhibits T cell response by limiting mitobiogenesis via matrix substrate-level phosphorylation arrest

  1. Amijai Saragovi
  2. Ifat Abramovitch
  3. Ibrahim Omar
  4. Eliran Arbib
  5. Ori Toker
  6. Eyal Gottlieb
  7. Michael Berger  Is a corresponding author
  1. Hebrew University, Israel
  2. Technion - Israel Institute of Technology, Israel
  3. Shaare Zedek Medical Center, Israel
https://doi.org/10.7554/eLife.56612
Share this article
Cite this article
  1. Amijai Saragovi
  2. Ifat Abramovitch
  3. Ibrahim Omar
  4. Eliran Arbib
  5. Ori Toker
  6. Eyal Gottlieb
  7. Michael Berger
(2020)
Systemic hypoxia inhibits T cell response by limiting mitobiogenesis via matrix substrate-level phosphorylation arrest
eLife 9:e56612.
https://doi.org/10.7554/eLife.56612
  2. Download BibTeX
  3. Download .RIS

Abstract

Systemic oxygen restriction (SOR) is prevalent in numerous clinical conditions, including chronic obstructive pulmonary disease (COPD),and is associated with increased susceptibility to viral infections. However, the influence of SOR on T cell immunity remains uncharacterized. Here we show the detrimental effect of hypoxia on mitochondrial-biogenesis in activated mouse CD8+ T cells. We find that low oxygen level diminishes CD8+ T cell viral response in vivo. We reveal that respiratory restriction inhibits ATP-dependent matrix processes that are critical for mitochondrial biogenesis. This respiratory restriction-mediated effect could be rescued by TCA cycle re-stimulation, which yielded increased mitochondrial matrix-localized ATP via substrate-level phosphorylation. Finally, we demonstrate that the hypoxia-arrested CD8+ viral response could be rescued in vivo through brief exposure to atmospheric oxygen pressure. Overall, these findings elucidate the detrimental effect of hypoxia on mitochondrial-biogenesis in activated CD8+ T cells, and suggest a new approach for reducing viral infections in COPD.

Data availability

Metabolic analysis data and Protein MS analysis have been deposited in OSF under DOI 10.17605/OSF.IO/JKMQF

The following data sets were generated

Article and author information

Author details

  1. Amijai Saragovi

    Immunology and Cancer Research, Hebrew University, Jerusalem, Israel
    Competing interests
    The authors declare that no competing interests exist.

  2. Ifat Abramovitch

    The Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel
    Competing interests
    The authors declare that no competing interests exist.

  3. Ibrahim Omar

    Immunology and Cancer Research, Hebrew University, Jerusalem, Israel
    Competing interests
    The authors declare that no competing interests exist.

  4. Eliran Arbib

    Immunology and Cancer Research, Hebrew University, Jerusalem, Israel
    Competing interests
    The authors declare that no competing interests exist.

  5. Ori Toker

    Department of Pediatrics, Allergy and Clinical Immunology Service, Shaare Zedek Medical Center, Jerusalem, Israel
    Competing interests
    The authors declare that no competing interests exist.

  6. Eyal Gottlieb

    The Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel
    Competing interests
    The authors declare that no competing interests exist.

  7. Michael Berger

    Immunology and Cancer Research, Hebrew University, Jerusalem, Israel
    For correspondence
    michaelb@ekmd.huji.ac.il
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3469-0076

Funding

Israeli Science Foundation (Personal grant,1596/17)

  • Michael Berger

German Israeli Foundation for Scientific Research and Development (I-1474-414.13/2018)

  • Michael Berger

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was performed in strict accordance with the guidelines of the institutional ethics committee (AAALAC standard). The protocols were approved by the Committee on the Ethics of Animal Experiments of the Hebrew University (Ethics Committee - research number: MD-16-14863-1 and MD-18-15662-5). Every effort was made to minimize suffering.

Human subjects: Human blood samples were obtained via Shaare Zedek Medical Center Jerusalem, Helsinki committee approval number: 143/14

Copyright

© 2020, Saragovi et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,721
    views
  • 315
    downloads
  • 12
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Amijai Saragovi
  2. Ifat Abramovitch
  3. Ibrahim Omar
  4. Eliran Arbib
  5. Ori Toker
  6. Eyal Gottlieb
  7. Michael Berger
(2020)
Systemic hypoxia inhibits T cell response by limiting mitobiogenesis via matrix substrate-level phosphorylation arrest
eLife 9:e56612.
https://doi.org/10.7554/eLife.56612

Share this article

https://doi.org/10.7554/eLife.56612

Categories and tags

Research organism

Further reading

    1. Immunology and Inflammation

    Follicular helper- and peripheral helper-like T cells drive autoimmune disease in human immune system mice

    Mohsen Khosravi-Maharlooei, Andrea Vecchione ... Megan Sykes
    Research Article

    Human immune system (HIS) mice constructed in various ways are widely used for investigations of human immune responses to pathogens, transplants, and immunotherapies. In HIS mice that generate T cells de novo from hematopoietic progenitors, T cell-dependent multisystem autoimmune disease occurs, most rapidly when the human T cells develop in the native NOD.Cg- Prkdcscid Il2rgtm1Wjl (NSG) mouse thymus, where negative selection is abnormal. Disease develops very late when human T cells develop in human fetal thymus grafts, where robust negative selection is observed. We demonstrate here that PD-1+CD4+ peripheral (Tph) helper-like and follicular (Tfh) helper-like T cells developing in HIS mice can induce autoimmune disease. Tfh-like cells were more prominent in HIS mice with a mouse thymus, in which the highest levels of IgG were detected in plasma, compared to those with a human thymus. While circulating IgG and IgM antibodies were autoreactive to multiple mouse antigens, in vivo depletion of B cells and antibodies did not delay the development of autoimmune disease. Conversely, adoptive transfer of enriched Tfh- or Tph-like cells induced disease and autoimmunity-associated B cell phenotypes in recipient mice containing autologous human APCs without T cells. Tfh/Tph cells from mice with a human thymus expanded and induced disease more rapidly than those originating in a murine thymus, implicating HLA-restricted T cell-APC interactions in this process. Since Tfh, Tph, autoantibodies, and lymphopenia-induced proliferation (LIP) have all been implicated in various forms of human autoimmune disease, the observations here provide a platform for the further dissection of human autoimmune disease mechanisms and therapies.

    1. Cell Biology
    2. Immunology and Inflammation

    RAS–p110α signalling in macrophages is required for effective inflammatory response and resolution of inflammation

    Alejandro Rosell, Agata Adelajda Krygowska ... Esther Castellano Sanchez
    Research Article

    Macrophages are crucial in the body’s inflammatory response, with tightly regulated functions for optimal immune system performance. Our study reveals that the RAS–p110α signalling pathway, known for its involvement in various biological processes and tumourigenesis, regulates two vital aspects of the inflammatory response in macrophages: the initial monocyte movement and later-stage lysosomal function. Disrupting this pathway, either in a mouse model or through drug intervention, hampers the inflammatory response, leading to delayed resolution and the development of more severe acute inflammatory reactions in live models. This discovery uncovers a previously unknown role of the p110α isoform in immune regulation within macrophages, offering insight into the complex mechanisms governing their function during inflammation and opening new avenues for modulating inflammatory responses.

    1. Immunology and Inflammation
    2. Microbiology and Infectious Disease

    Monoclonal antibodies derived from B cells in subjects with cystic fibrosis reduce Pseudomonas aeruginosa burden in mice

    Malika Hale, Kennidy K Takehara ... Marion Pepper
    Research Article

    Pseudomonas aeruginosa (PA) is an opportunistic, frequently multidrug-resistant pathogen that can cause severe infections in hospitalized patients. Antibodies against the PA virulence factor, PcrV, protect from death and disease in a variety of animal models. However, clinical trials of PcrV-binding antibody-based products have thus far failed to demonstrate benefit. Prior candidates were derivations of antibodies identified using protein-immunized animal systems and required extensive engineering to optimize binding and/or reduce immunogenicity. Of note, PA infections are common in people with cystic fibrosis (pwCF), who are generally believed to mount normal adaptive immune responses. Here, we utilized a tetramer reagent to detect and isolate PcrV-specific B cells in pwCF and, via single-cell sorting and paired-chain sequencing, identified the B cell receptor (BCR) variable region sequences that confer PcrV-specificity. We derived multiple high affinity anti-PcrV monoclonal antibodies (mAbs) from PcrV-specific B cells across three donors, including mAbs that exhibit potent anti-PA activity in a murine pneumonia model. This robust strategy for mAb discovery expands what is known about PA-specific B cells in pwCF and yields novel mAbs with potential for future clinical use.